See more : Shaoxing BSM Chemical Co., Ltd. (300796.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of China NT Pharma Group Company Limited (1011.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China NT Pharma Group Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Indofood CBP Sukses Makmur Tbk (PIFFY) Income Statement Analysis – Financial Results
- Columbus McKinnon Corporation (CMCO) Income Statement Analysis – Financial Results
- V.F. Corporation (0R30.L) Income Statement Analysis – Financial Results
- Sinostone(Guangdong) Co.,Ltd. (001212.SZ) Income Statement Analysis – Financial Results
- Limitless X Holdings Inc. (VYBE) Income Statement Analysis – Financial Results
China NT Pharma Group Company Limited (1011.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ntpharma.com
About China NT Pharma Group Company Limited
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufactures, sells, and trades in prescription medicines for the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products and generic drugs. The company also provides marketing and promotion services to suppliers, and logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Suzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.37M | 207.09M | 226.70M | 221.73M | 365.97M | 571.52M | 604.85M | 915.12M | 847.73M | 864.62M | 754.12M | 739.13M | 2.76B | 2.67B |
| Cost of Revenue | 0.00 | 81.81M | 81.24M | 86.83M | 105.09M | 149.52M | 120.61M | 421.49M | 396.22M | 473.28M | 465.15M | 467.31M | 1.87B | 2.00B |
| Gross Profit | 7.37M | 125.29M | 145.46M | 134.90M | 260.88M | 422.00M | 484.24M | 493.63M | 451.51M | 391.34M | 288.97M | 271.82M | 890.65M | 663.20M |
| Gross Profit Ratio | 100.00% | 60.50% | 64.16% | 60.84% | 71.29% | 73.84% | 80.06% | 53.94% | 53.26% | 45.26% | 38.32% | 36.78% | 32.29% | 24.86% |
| Research & Development | 0.00 | 3.76M | 5.96M | 9.00M | 17.09M | 34.19M | 8.42M | 6.91M | 4.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 63.57M | 59.88M | 80.66M | 96.25M | 163.82M | 178.99M | 151.84M | 110.07M | 90.98M | 81.44M | 91.22M | 129.30M | 129.08M | 90.06M |
| Selling & Marketing | 0.00 | 46.24M | 149.86M | 123.07M | 93.02M | 183.48M | 91.85M | 201.45M | 228.90M | 264.58M | 375.81M | 579.83M | 452.83M | 354.46M |
| SG&A | 63.57M | 106.12M | 230.52M | 219.33M | 256.84M | 362.48M | 243.69M | 311.52M | 319.88M | 346.03M | 467.02M | 709.12M | 581.92M | 444.51M |
| Other Expenses | -56.21M | 11.44M | -2.13M | -1.50M | -2.04M | -302.16M | 16.79M | 3.27M | -26.51M | 598.00K | 678.00K | 224.00K | -56.82M | -36.85M |
| Operating Expenses | 7.37M | 117.56M | 228.39M | 217.82M | 254.81M | 361.49M | 229.25M | 308.79M | 293.36M | 342.52M | 464.41M | 707.00M | 525.09M | 407.67M |
| Cost & Expenses | 7.37M | 199.36M | 309.63M | 304.65M | 359.89M | 511.00M | 349.86M | 730.28M | 689.58M | 815.80M | 929.56M | 1.17B | 2.39B | 2.41B |
| Interest Income | 9.00K | 24.00K | 239.00K | 2.84M | 1.88M | 2.10M | 94.00K | 4.06M | 5.70M | 21.07M | 21.97M | 6.43M | 3.41M | 0.00 |
| Interest Expense | 28.82M | 71.73M | 88.73M | 85.11M | 103.05M | 80.36M | 42.72M | 27.74M | 26.62M | 78.04M | 70.32M | 52.22M | 58.08M | 45.38M |
| Depreciation & Amortization | 5.88M | 21.07M | 42.25M | 24.40M | 31.13M | 35.65M | 34.42M | 23.01M | 15.93M | 23.16M | 27.08M | 27.62M | 24.24M | 17.42M |
| EBITDA | 1.33M | 10.40M | -17.78M | -43.74M | -155.97M | -210.92M | 303.57M | 86.29M | 143.25M | 118.54M | -555.44M | -1.10B | 389.80M | 272.96M |
| EBITDA Ratio | 18.06% | 19.08% | -7.51% | -19.73% | 2.48% | -36.90% | 51.51% | 23.30% | 20.19% | 10.38% | -17.38% | -56.78% | 14.13% | 10.23% |
| Operating Income | 0.00 | 18.44M | -59.28M | -68.13M | -22.05M | -246.56M | 269.58M | 185.67M | 135.96M | 96.07M | -577.64M | -1.12B | 365.55M | 255.54M |
| Operating Income Ratio | 0.00% | 8.90% | -26.15% | -30.73% | -6.02% | -43.14% | 44.57% | 20.29% | 16.04% | 11.11% | -76.60% | -151.15% | 13.25% | 9.58% |
| Total Other Income/Expenses | -33.37M | -23.50M | -89.48M | -117.37M | -148.98M | -315.44M | 1.35M | -29.03M | -35.25M | -78.74M | -75.20M | -60.10M | -58.08M | -45.38M |
| Income Before Tax | -33.37M | -54.30M | -148.75M | -200.29M | -583.47M | -562.00M | 226.43M | 156.60M | 100.71M | 17.33M | -652.84M | -1.18B | 307.47M | 210.16M |
| Income Before Tax Ratio | -453.01% | -26.22% | -65.62% | -90.33% | -159.43% | -98.33% | 37.44% | 17.11% | 11.88% | 2.00% | -86.57% | -159.28% | 11.15% | 7.88% |
| Income Tax Expense | 122.00K | 12.11M | 2.58M | -9.02M | 9.73M | 39.86M | 15.88M | 40.84M | 13.01M | 15.24M | 20.62M | -67.97M | 73.09M | 80.75M |
| Net Income | -143.59M | -66.41M | -151.33M | -191.27M | -593.20M | -957.67M | 165.20M | 116.18M | 87.69M | 2.09M | -673.46M | -1.11B | 234.38M | 128.61M |
| Net Income Ratio | -1,949.36% | -32.07% | -66.76% | -86.26% | -162.09% | -167.56% | 27.31% | 12.70% | 10.34% | 0.24% | -89.30% | -150.08% | 8.50% | 4.82% |
| EPS | -0.04 | -0.04 | -0.08 | -0.10 | -0.34 | -0.61 | 0.11 | 0.08 | 0.06 | 0.00 | -0.62 | -1.03 | 0.23 | 0.16 |
| EPS Diluted | -0.17 | -0.04 | -0.08 | -0.10 | -0.34 | -0.61 | 0.09 | 0.07 | 0.06 | 0.00 | -0.62 | -1.03 | 0.23 | 0.16 |
| Weighted Avg Shares Out | 848.12M | 1.90B | 1.89B | 1.89B | 1.76B | 1.57B | 1.71B | 1.55B | 1.42B | 1.08B | 1.08B | 1.08B | 1.00B | 811.44M |
| Weighted Avg Shares Out (Dil) | 197.82M | 1.90B | 1.89B | 1.89B | 1.76B | 1.57B | 1.71B | 1.56B | 1.43B | 1.08B | 1.08B | 1.08B | 1.01B | 815.63M |
Source: https://incomestatements.info
Category: Stock Reports